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Abstract
Background: In addition to anti-citrullinated protein antibodies (ACPAs), antibodies targeting carbamylated (i.e.,
homocitrullinated) proteins (anti-CarP antibodies) have been described in rheumatoid arthritis (RA). However, the
extent to which anti-CarP antibodies are truly distinct from ACPA remains unclear, and few studies have focused on
specific autoantigens. Here, we examine cross-reactivity between ACPA and anti-CarP antibodies, in the context of
the candidate autoantigen α-enolase.
Methods: Cross-reactivity was examined by immunoblotting of citrullinated and carbamylated proteins using
purified ACPA; and by peptide absorption experiments, using the citrullinated α-enolase peptide CEP-1 and a
homocitrulline-containing version (carb-CEP-1) in ELISA. The population-based case-control cohort EIRA (n = 2836 RA;
373 controls) was screened for reactivity with CEP-1 and carb-CEP-1, using the ISAC multiplex array. Associations
between anti-CarP antibodies, smoking and genetic risk factors were analysed using unconditional logistic regression
models. Differences in antibody levels were investigated using the Mann-Whitney U test.
Results: Affinity-purified ACPA was found to bind carbamylated proteins and homocitrulline-containing peptides,
demonstrating definitive cross-reactivity between ACPA and anti-CarP antibodies. Anti-carb-CEP-1 reactivity in EIRA was
almost exclusively confined to the CEP-1-positive subset, and this group of RA patients (21 %) displayed a particularly
strong ACPA response with marked epitope spreading. The small RA subset (3 %) with homocitrulline reactivity in the
absence of citrulline reactivity did not associate with smoking or risk genes, and importantly had significantly lower
anti-carb-CEP-1 antibody levels.
Conclusion: Our data presented herein cast doubt on the specificity of anti-CarP antibodies in RA, which we posit may
be a subset of cross-reactive ACPA.
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Background
Autoantibodies to citrullinated proteins (ACPA) are today
a well-known and accepted feature of rheumatoid arthritis
(RA) [1, 2]. These autoantibodies have been linked to RA
risk factors, most notably HLA-DRB1 shared epitope (SE)
alleles and cigarette smoking, and their presence predicts
a more destructive disease process [3–7]. However, des-
pite the identification of several putative citrullinated
autoantigens, including fibrinogen [8], vimentin [9], type
II collagen [10], α-enolase [11] and histone 4 [12], the
specific in vivo ACPA targets triggering autoimmunity
and driving disease remain obscure.
More recently, antibodies to carbamylated proteins
containing homocitrulline (anti-CarP antibodies) were
described in RA [13]. Protein carbamylation, or homoci-
trullination, is an enzyme-independent post-translational
modification of lysine residues by isocyanate, present
in, for example, cigarette smoke [14]. As smoking is a
well-described risk factor for RA [15, 16], it has been
proposed that smoking could be linked to anti-CarP
antibodies in RA via increased carbamylation and the
subsequent production of anti-CarP antibodies [17–19].
However, scientific data in support of this hypothesis has
yet to be presented. Anti-CarP antibodies are specific for
RA [20] and reportedly distinct from ACPA, based on the
detection of anti-CarP antibodies in ACPA-negative dis-
ease [13, 21, 22]. However, in the Swedish Epidemiological
Investigation of RA (EIRA) study and in the Dutch
Early Arthritis Clinic (EAC) cohort, we recently showed
that only 4–7 % of RA patients were anti-CarP antibody-
positive in the absence of ACPA. Notably, there was no
specific association between HLA-DRB1 SE or smoking
and anti-CarP antibodies, when the analyses were adjusted
for the presence of ACPA [21].
In addition, the widely used biochemical assay for de-
tection of peptidylcitrulline, the so-called Senshu method
[23] where rabbit polyclonal antibodies bind chemically
modified citrulline residues, was found to also detect
homocitrulline [24] and purified ACPA have been shown
to bind not only citrullinated fibrinogen, but also carba-
mylated fibrinogen [20].
The extent to which these two autoantibody specificities
are cross-reactive, and the association between these anti-
bodies and environmental and genetic risk factors for RA,
has not been thoroughly explored, and as yet, only fibrino-
gen and more recently vimentin have been studied in this
context [13, 20, 21, 24–26]. Therefore, it is imperative that
more work on specific antigens is performed in order to
fully understand the relationship between ACPA and anti-
CarP antibodies in the aetiopathology of RA [19].
Citrullinated α-enolase has long been scrutinized as a
potential target for ACPA in RA [11, 27–34]. Antibodies
to CEP-1, the immunodominant B cell epitope of citrul-
linated α-enolase [27] are found in approximately 40 %
of patients with RA, and have been associated with SE,
PTPN22 and smoking [28, 32]. Hence, in the present
study, we have investigated the antibody responses to
citrullinated and carbamylated α-enolase and their relation




The present study includes patients newly diagnosed with
RA (cases) and age-matched, sex-matched and residential
area-matched controls from the Swedish Epidemiological
Investigation of RA (EIRA) cohort. Information on
cigarette smoking (“ever smoker” or “never smoker”)
was obtained via self-reported questionnaire at baseline
[16]. Genotyping of HLA-DRB1 shared epitope (SE) alleles
and the protein tyrosine phosphatase gene (PTPN22
rs2476601) was performed on blood samples obtained
within one week of the RA diagnosis [5, 35]. Smoking
and genetic data for the present study were retrieved
from the EIRA database on 2784, 2235 and 2477 patients
with RA and 4864, 1923 and 1936 controls, for smoking, SE
and PTPN22, respectively. For antibody purification, plasma
samples from patients with RA with a strong anti-CEP-1
antibody response (n = 5) or a strong anti-CCP2 antibody
response (n = 38) were collected at the Rheumatology Clinic,
Karolinska University Hospital Solna, Stockholm, Sweden.
Informed consent was obtained from participating patients
and controls, and ethical approvals for the study was granted
at the regional ethics review board at Karolinska Institutet,
Stockholm, Sweden.
Antigens
Three cyclic peptides corresponding to amino acid 5-21
of full-length α-enolase were synthesized by Innovagen
(Malmö, Sweden): the original CEP-1 peptide containing
two citrulline residues (CEP-1) [27]; the arginine-containing
control peptide REP-1; and a version of CEP-1 contain-
ing homocitrulline in the place of citrulline, denoted
carb-CEP-1 (Additional file 1: Table S1).
Recombinant human α-enolase, produced in-house, and
purified human fibrinogen (Enzyme Research, South Bend,
IN, USA) depleted of immunoglobulins, were citrullinated
or carbamylated in vitro. Citrullination was performed for
2 h at 37 °C, at a protein concentration of 1 mg/ml, in
peptidylarginine deiminase (PAD) buffer (100 mM Tris,
10 mM CaCl2, 5 mM dithiothreitol (DTT), pH 7.6)
using 2 U/mg of rabbit skeletal muscle PAD2 enzyme
(Sigma, St. Louis, MO, USA). The reaction was stopped
by the addition of 20 mM ethylenediaminetetraacetic
acid (EDTA), followed by extensive dialysis to calcium-
free PBS. Carbamylated proteins were produced by in-
cubating α-enolase and fibrinogen in PBS at 1 mg/ml in
the presence of 100 mM potassium cyanate (KOCN)
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(Sigma) overnight at 37 °C, followed by extensive dialysis
to calcium-free PBS. Successful citrullination and car-
bamylation were confirmed by mass spectrometry (data
not shown). For a detailed description of the mass spec-
trometry analysis see Additional file 1: Supplementary
methods.
Affinity purification of ACPA IgG
Plasma samples (n = 43) were centrifuged and diluted in
PBS (1:5 v/v) before applied to Protein G HP columns
(GE Healthcare) for whole IgG enrichment. To further
purify CEP-1-specific IgG, REP-1 and CEP-1 peptides
(1 mg/ml) were directly coupled to 1 ml NHS-Sepharose
columns (GE Healthcare), and anti-CEP-1 IgG from five
anti-CEP-1 antibody-positive serum samples was subse-
quently purified from whole IgG using the CEP-1 affinity
column, after pre-absorption on the REP-1 column to re-
move non-citrulline-specific antibodies. Bound antibodies
were eluted with 0.1 M glycine-HCl (pH 2.7) and directly
neutralized with 1 M Tris (pH 9). Column flow-through
(FT) fractions depleted of anti-CEP-1 IgG were collected
in parallel. MicrosepTM UF Centrifugal Devices (Pall Life
Science, Port Washington, NY, USA) were used in ac-
cordance with the manufacturer’s instructions, to concen-
trate the antibodies and to change the buffer into PBS.
Anti-CCP2-reactive IgG from 38 anti-CCP2-positive RA
serum samples were pooled after purification on CCP2-
columns kindly donated by EuroDiagnostica AB, Malmö,
Sweden, as previously described [36].
Antibody detection using ISAC and ELISA
High-throughput anti-CEP-1, anti-REP-1 and anti-carb-
CEP-1 antibody screening of serum samples from 2836
patients with RA from the EIRA cohort and 373 EIRA con-
trols was accomplished using a custom-made microarray
based on the ImmunoCAP immuno solid-phase allergen
chip multiplex assay (ISAC) microarray system (Phadia AB,
Uppsala, Sweden) containing the peptides of interest, as
previously described [25, 37]. This microarray also contains
a large number of other citrullinated peptides derived from
different proteins, including fibrinogen, vimentin and
collagen type II, and their corresponding arginine-
containing control peptides. Cut offs for antibody posi-
tivity were calculated based on the 98th percentile among
the EIRA controls. A detailed description of the ISAC
method is provided in Additional file 1.
For testing the reactivity of the affinity-purified anti-
CEP-1 and FT IgG fractions, and for analysing the degree
of cross-reactivity between double-positive (CEP-1+/Carb-
CEP-1+) or single-positive (CEP-1+/Carb-CEP-1- and
CEP-1-/Carb-CEP-1+) EIRA RA serum samples, peptide
ELISAs detecting anti-CEP-1 and anti-Carb-CEP-1 IgG
were used as previously described [27, 28, 32] (see
Additional file 1: Supplementary methods for details).
Cross-reactivity assay
Anti-CEP-1/anti-Carb-CEP-1 double-positive serum sam-
ples (n = 4), anti-CEP-1 single-positive (n = 4), and anti-
Carb-CEP-1 single-positive serum samples (n = 4) were
selected for the cross-reactivity experiment. Serum sam-
ples were diluted 1:100 in radioimmunoassay (RIA) buffer
and incubated with 100 μg/ml of the CEP-1 or the
Carb-CEP-1 peptide for 2 h at room temperature (RT).
Following incubation, the absorbed serum was analysed
using the same protocol as for the peptide ELISA de-
scribed previously (see also Additional file 1).
Western blot
Citrullinated, carbamylated and unmodified proteins
(100 ng/well) were separated on NuPAGE® Bis-Tris 4-20 %
gels (Bio-Rad Laboratories, Hercules, CA, USA) and trans-
ferred to nitrocellulose membranes. Membranes were
blocked with 5 % milk in Tris-buffered saline/0.05 % Tween
and probed with a pool (n = 38) of purified anti-CCP2 IgG
(or the corresponding CCP2 column FT IgG pool) at
2 μg/ml overnight at 4 °C, then washed with PBS/0.05 %
Tween and incubated with HRP-conjugated goat anti-
human IgG (Jackson ImmunoResearch, West Grove, PA,
USA), diluted 1:10,000, for 1 h at RT. Bound antibody was
detected using ECL chemiluminescence (GE Healthcare).
Statistics
Patients were divided into four different subsets ac-
cording to the presence or absence of anti-CEP-1 and
anti-carb-CEP-1 IgG. The odds ratio (OR) and 95 %
confidence intervals (CI) for each RA subset, in relation
to smoking, SE and PTPN22, were calculated separately
through unconditional logistic regression models, adjusted
for matching variables (age, gender and residential area).
Exposed individuals were compared with unexposed indi-
viduals (smokers vs. non-smokers, carriers of any copy of
SE vs. non-carriers, carriers of the PTPN22 risk allele vs.
non-carriers). All analyses were implemented through
SAS V.9.3. Statistical differences in antibody levels and
number of ACPA fine specificities, between different
subsets, were determined by the Mann-Whitney U test
for independent groups. The same method was also used
to determine the relationship between anti-carb-CEP-1
antibody levels and SE/smoking.
Results
Purified ACPA IgG bind carbamylated proteins
Using a pool of affinity-purified anti-CCP2 IgG, previ-
ously described to bind both citrullinated α-enolase and
fibrinogen [36], we could demonstrate cross-reactivity of
human ACPA with carbamylated α-enolase for the first
time, and in line with previous reports [20, 24], we could
also show cross-reactivity with carbamylated fibrinogen
(Fig. 1a). There was no reactivity against unmodified
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proteins. The corresponding FT IgG pool bound neither
modified nor native proteins; only some weak unspecific
background staining was observed.
Purified anti-CEP-1 IgG displays cross-reactivity with a
homocitulline-containing version of CEP-1
To further investigate the specificity and extent of cross-
reactivity between citrullinated and carbamylated epitopes,
we focused on α-enolase and the immunodominant CEP-1
epitope. Affinity-purified anti-CEP-1-specific IgG bound
not only CEP-1 in ELISA, but also a version of CEP-1
(denoted carb-CEP-1) identical in sequence but with
citrulline residues replaced with homocitrullines. Anti-
CEP-1 IgG purified from different patients with RA showed
consistently strong binding to the CEP-1 peptide in ELISA
(data not shown), and in addition displayed varying de-
grees of binding to the carb-CEP-1 peptide (Fig. 1b).
Flow-through IgG from the same five patients did not
bind to CEP-1 or carb-CEP-1, demonstrating that the
carb-CEP-1 reactivity was confined to the anti-CEP-1
IgG eluate fraction. None of the anti-CEP-1 IgG column
eluates demonstrated reactivity to the control peptide
REP-1 (data not shown). Taken together, these data sug-
gest that citrullinated α-enolase-specific ACPA also have
the ability to bind homocitrulline-containing epitopes.
Anti-carb-CEP-1 reactivity in relation to anti-CEP-1 status
in EIRA
Using the large EIRA case-control cohort, we next sought
to determine the proportion of patients with RA with
antibodies binding to carb-CEP-1, and how this reactivity
correlated with CEP-1 positivity. Reactivity to CEP-1,
REP-1 and carb-CEP-1 was therefore analysed in serum
Fig. 1 Human anti-citrullinated protein antibodies (ACPA) cross-react with carbamylated epitopes. a Native (n), in vitro citrullinated (Cit) and in vitro
carbamylated (Carb) samples of recombinant human α-enolase and purified human fibrinogen were subjected to western blot using affinity-purified
anti-CCP2 IgG (ACPA IgG) and CCP2-depleted column flow-through IgG (FT IgG), obtained from a pool of 38 rheumatoid arthritis (RA) serum samples.
b Affinity-purified anti-CEP-1 IgG and the corresponding column FT IgG fractions from five patients with RA were tested for reactivity to the carb-CEP-1
peptide in ELISA; antibody levels are presented as optical density (OD)
Fig. 2 Reactivity to CEP-1 and homocitrullinated CEP-1 peptide (carb-CEP-1) in Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA)
rheumatoid arthritis (RA) cases. a Sera from 2836 patients with RA from the EIRA cohort were tested for reactivity with CEP-1 and carb-CEP-1 using the
immuno solid-phase allergen chip multiplex assay (ISAC) platform and divided into subsets. b Anti-carb-CEP-1 antibody levels were compared between
the CEP-1+/carb-CEP-1+ and CEP-1-/carb-CEP-1+ subsets. Antibody levels are presented as arbitrary units (AU)
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from 2836 RA cases using the ISAC platform. The fre-
quency of anti-CEP-1 antibody-positive patients with RA
was 41 %, which is in accordance with previous analyses
using a smaller proportion of EIRA (n = 1985 RA cases)
and the ELISA method [28, 32]. There was less than 2 %
reactivity towards the REP-1 control peptide, while 21 %
of patients with RA had reactivity towards the carb-CEP-1
peptide (Fig. 2a). Notably, almost all patients positive for
anti-carb-CEP-1 IgG were also positive for antibodies to
CEP-1. Only 3 % of EIRA RA serum samples had a unique
and specific reactivity with carb-CEP-1. Importantly,
anti-carb-CEP-1 antibody levels were significantly lower
in patients who were carb-CEP-1 single-positive than in
the CEP-1/carb-CEP-1 double-positive RA subset (Fig. 2b).
Furthermore, when increasing specificity to 100 %, the
carb-CEP-1 single-positive subset was almost completely
eliminated (<1 %) while the double-positive subset
remained (data not shown), suggesting that carb-CEP-1
reactivity in the absence of CEP-1 reactivity is extremely
rare.
Cross-reactivity between CEP-1 and carb-CEP-1
In order to more directly determine whether the anti-
carb-CEP-1 antibody response was simply the result of
homocitrulline-cross-reactive anti-CEP-1 antibodies, we
subsequently performed peptide absorption experiments.
In these experiments we demonstrated that ACPA from
different patients with RA displayed varying degrees of
cross-reactivity to the homocitrulline-containing CEP-1
homologue, carb-CEP-1. In a selection of 16 RA serum
samples, we examined whether the CEP-1 peptide and/or
the carb-CEP-1 peptide could inhibit antibody binding
to CEP-1 and/or carb-CEP. Not surprisingly, in CEP-1
positive sera, pre-incubation with the CEP-1 peptide
completely inhibited (100 %) all CEP-1 reactivity, while
inhibition with the carb-CEP-1 peptide was less efficient
(4–49 %) in blocking binding to CEP-1 (Fig. 3a). Notably,
the anti-carb-CEP-1 antibody response in double-positive
sera was blocked efficiently by both CEP-1 and carb-CEP-
1 pre-incubation, while in the rare group of carb-CEP-1
single-positive subjects, more varying degrees of inhibition
was seen (Fig. 3b). Two serum samples had almost
complete inhibition of binding to carb-CEP-1 after
both CEP-1 and carb-CEP-1 pre-incubation, while the
CEP-1 peptide did not inhibit binding to carb-CEP-1
in the two serum samples that displayed a very strong
anti-carb-CEP-1 IgG response (optical density (OD)
values >3.5 AU/ml).
Anti-carb-CEP-1 reactivity in relation to smoking in EIRA
Based on the link between smoking and carbamylation
and the association between smoking and RA [14–16],
we next investigated the role of smoking in the develop-
ment of anti-carb-CEP-1 antibodies. Our first analysis
showed that smoking was associated with anti-carb-CEP-1
positivity, and with elevated anti-carb-CEP-1 antibody
levels (data not shown). However, we have previously
shown that smoking is strongly associated with anti-CEP-1
antibodies [28, 32], and as the majority of anti-carb-CEP-1
Fig. 3 Homocitrullinated CEP-1 peptide (Carb-CEP-1) reactivity results from cross-reactive anti-CEP-1 antibodies. To assess cross-reactivity between
CEP-1 and carb-CEP-1, serum from patients positive for either anti-CEP-1 antibodies only (n = 4) or for anti-carb-CEP-1 antibodies only (n = 4), and
serum from patients positive for both anti-CEP-1 and anti-carb-CEP-1 antibodies (n = 4), were pre-absorbed by incubating with either dilution buffer,
CEP-1 peptide or carb-CEP-1 peptide. Levels of anti-CEP-1 (a) and anti-carb-CEP-1 (b) antibodies were subsequently measured by ELISA, and presented
as optical density (OD). EIRA Swedish Epidemiological Investigation of Rheumatoid Arthritis cohort
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reactivity was confined to the CEP-1-positive subset, we
also had to consider CEP-1 reactivity in the analysis. Hence,
we divided the patients with RA into four subsets, based on
presence or absence of carb-CEP-1 and/or CEP-1 reactivity.
With this division, we found that smoking was significantly
associated with anti-CEP-1 single-positive RA, with an odds
ratio of 2.21 (95 % CI 1.82, 2.68), and with CEP-1/carb-
CEP-1 double-positive disease (OR = 2.6; 95 % CI 2.07,
3.25), but not with anti-carb-CEP-1 single-positive disease
(OR = 1.15; 95 % CI 0.71, 1.86) (Table 1). Importantly, there
was no statistical difference when comparing ORs for the
double-positive vs. the CEP-1 single-positive subset (2.6 vs.
2.21, p = 0.37), suggesting that smoking has no specific
effect on the development of anti-CarP antibodies, in
line with our previous data [21].
Anti-carb-CEP-1 reactivity in relation to HLA-DRB1 SE in EIRA
A similar analysis to that used for smoking was also
performed for HLA-DRB1 SE, and again there was sig-
nificant association between HLA-DRB1 SE and both
anti-carb-CEP-1 antibody positivity and elevated anti-
carb-CEP-1 antibody levels (data not shown). When
subdividing patients, the association with the SE was
significantly stronger in CEP-1 single-positive RA (OR =
6.58; 95 % CI 5.01, 8.65) than with carb-CEP-1 single-
positive RA (OR = 2.07; 95 % CI 1.19, 3.61), (6.58 vs. 2.07,
p = 0.0002) (Table 2). However, contrary to the smoking
data, the association between the SE and the double-
positive subset (OR = 10.42; 95 % CI 7.2, -14.90) was
significantly stronger than with the CEP-1 single-positive
subset (10.42 vs. 6.58, p = 0.03), suggesting an SE-mediated
effect on the development of carb-(cross)-reactive
antibodies.
Anti-carb-CEP-1 reactivity in relation to PTPN22 in EIRA
We also investigated the association of PTPN22 poly-
morphism with the presence of anti-carb-CEP-1 antibodies,
in relation to the anti-CEP-1 antibody response. PTPN22
differed from smoking and SE, in the sense that there was
no difference in the association between CEP-1 single-
positive (OR = 1.90; 95 % CI 1.54, 2.35) and carb-CEP-1
single-positive (OR = 2.05; 95 % CI 1.19, 3.51) disease (1.90
Table 1 Association between smoking and RA in subgroups of
patients, divided based on the presence/absence of anti-CEP-1
and anti-carb-CEP-1 antibodies
CEP-1/carb-CEP-1 Smoking ORa (95 % CI)
Never Ever
Controls 2114 (43.46) 2750 (56.54) Reference 1.0
–/– 575 (37.00) 979 (63.00) 1.23b (1.09, 1.39)
+/– 159 (24.54) 489 (75.46) 2.21b (1.82, 2.68)
–/+ 29 (38.67) 46 (61.33) 1.15 (0.71, 1.86)
+/+ 107 (21.10) 400 (78.90) 2.60b (2.07, 3.25)
CEP-1 citrullinated α-enolase peptide-1, carb-CEP-1 carbamylated CEP-1, CI
confidence interval, RA rheumatoid arthritis. aOdds ratios (OR) were adjusted
for age, gender and residential area. bStatistically significant ORs
Table 2 Association between HLA-DRB1 SE alleles and RA in
subgroups of patients, divided based on the presence/absence
of anti-CEP-1 and anti-carb-CEP-1 antibodies
CEP-1/carb-CEP-1 SE ORa (95 % CI)
None Any
Controls 959 (49.87) 964 (50.13) Reference 1.0
–/– 468 (37.23) 789 (62.77) 1.69b (1.46, 1.97)
+/– 70 (13.65) 443 (86.35) 6.58b (5.01, 8.65)
–/+ 20 (32.79) 41 (67.21) 2.07b (1.19, 3.61)
+/+ 36 (8.91) 368 (91.09) 10.42b (7.28, 14.90)
SE shared epitope, CEP-1 citrullinated α-enolase peptide-1, carb-CEP-1 carbamylated
CEP-1, CI confidence interval, RA rheumatoid arthritis. aOdds ratios (OR) were
adjusted for age, gender and residential area. bStatistically significant ORs
Fig. 4 The anti-citrullinated protein antibody (ACPA) response is stronger in CEP-1/homocitrullinated CEP-1 peptide (carb-CEP-1) double-positive
rheumatoid arthritis (RA) than in CEP-1 single-positive RA. Anti-CEP-1 IgG (a), anti-CCP2 IgG (b), and the number of ACPA fine specificities (c) were
compared between the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) cohort RA CEP-1+/carb-CEP-1- and CEP-1+/carb-CEP-1+
subsets (****p < 0.0001). Data in a and c were generated using the immuno solid-phase allergen chip multiplex assay (ISAC) microarray; data in b were
generated by ELISA. AU arbitrary units
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vs. 2.05, p = 0.85), and having both antibody reactivities
(OR = 2.07; 95 % CI 1.64, 2.6) did not significantly alter the
association either (1.90 vs. 2.07, p = 0.73) (Additional file 1:
Table S2).
Anti-carb-CEP-1 reactivity in relation to the overall ACPA
response in EIRA
Finally we analysed anti-CEP-1 IgG levels, anti-CCP2 IgG
levels, and the number of ACPA fine specificities in
CEP-1 single-positive RA, compared to CEP-1/carb-CEP-1
double-positive RA. Higher anti-CEP-1 and anti-CCP2 IgG
levels were detected in the double-positive subset, and a
higher number of ACPA fine specificities were recorded in
CEP-1/carb-CEP-1 double-positive patients with RA, com-
pared to CEP-1 single-positive patients; all values were sig-
nificant with p values <0.0001 (Fig. 4). These results clearly
demonstrate a stronger anti-CEP-1 antibody response and
a stronger overall ACPA response in the subset with carb-
CEP-1 (cross)-reactive antibodies.
Discussion
This is the first report of an antibody response to carba-
mylated α-enolase in RA. Previous reports on anti-CarP
antibodies in RA have focused mainly on carbamylated
fibrinogen or the complex protein mixture of carbamy-
lated fetal calf serum [13, 20–22, 24, 25], and recently a
report was published on antibodies against carbamylated
vimentin (26). Our study suggests that the anti-CarP
antibody response in RA can be explained by cross-reactive
ACPA. This conclusion was particularly evident from
immunoblotting experiments using affinity-purified
anti-CCP2 IgG molecules. Purified ACPA bound not only
citrullinated α-enolase and citrullinated fibrinogen, but
also carbamylated α-enolase and -fibrinogen, while un-
modified proteins were not targeted, and importantly,
ACPA-depleted IgG was not able to recognize citrulli-
nated or carbamylated epitopes. Notably, the two earli-
est reports linking carbamylation to the development of
arthritis in mouse models already describe cross-reactivity
between citrulline- and homocitrulline-containing epitopes
[17, 18].
Using a synthetic and artificial peptide based on the
well-characterised CEP-1 epitope from citrullinated α-
enolase [27, 28, 32] but with homocitrulline in place of
citrulline (amino acids 9 and 15), we showed that
approximately 20 % of patients with RA in the EIRA
cohort had antibodies to carb-CEP-1. While the carb-
CEP-1 peptide most likely does not represent an in vivo
antigenic target (amino acid 9 and 15 of unmodified
α-enolase are arginines, not lysines), and any biological and
mechanistic implications based on the peptide data there-
fore are limited, the observed cross-reactivity between
anti-CEP-1 IgG and carb-CEP-1 suggests that antibodies
to citrullinated α-enolase can also bind to homocitrulline-
containing epitopes. The fact that the anti-carb-CEP-1
antibody-positive subset of patients was almost exclusively
confined to the CEP-1-positive population, together
with the observation that CEP-1 could block carb-CEP-1
reactivity much more efficiently than carb-CEP-1 could
block CEP-1 reactivity, clearly supports our interpret-
ation; that is, that the reactivity measured as anti-CarP-
antibodies are for the most part represented by cross-
reactive ACPA.
The group of patients with anti-carb-CEP-1 antibodies
had higher anti-CEP-1 antibody levels, but also higher
anti-CCP2 antibody levels, and a broader ACPA reper-
toire (than anti-CEP-1 antibody-positive patients without
anti-carb-CEP-1 antibodies), suggesting a stronger ACPA
response in general in this group of patients, with epitope
spreading and more promiscuous antigen-recognition,
i.e., also including epitopes containing homocitrulline,
which is structurally very similar to citrulline. Our gene-
environment association data suggest that this extended
antibody reactivity is influenced by HLA-DRB1 SE alleles,
but not by PTPN22 or smoking.
Recently, anti-CarP antibodies have also been de-
scribed in small subsets of patients with non-RA early
arthritis [38], and in a large portion of patients with pri-
mary Sjögren’s syndrome [39], where the presence of anti-
CarP antibodies correlated with disease severity. Contrary
to our conclusion, these reports seem to indicate that this
class of autoantibodies could be more of a general marker
for inflammation than cross-reactive ACPAs, which would
be specific for RA.
Taken together, our data seem to suggest that
cross-reactivity between ACPA and anti-CarP anti-
bodies in RA is a common phenomenon. Here, we
have described this cross-reactivity in the context of
the RA candidate autoantigen α-enolase. However,
supported by recent work from Scinocca and colleagues,
demonstrating cross-reactivity between citrullinated and
carbamylated fibrinogen [20], we posit that this is also
likely the case for other citrullinated/carbamylated anti-
gens. In line with previous reports [20, 24], this cross-
reactivity is not complete or consistent, and indeed a small
percentage (3 %) of RA cases in our study demonstrated
reactivity exclusively to the carb-CEP-1 peptide and not
CEP-1. However, this subset of patients was almost com-
pletely eliminated when using a more stringent cut off for
positivity, casting doubt on the existence of specific anti-
CarP antibodies.
Conclusions
ACPAs are cross-reactive with homocitrullinated epitopes
on α-enolase. This calls into question the specificity of
anti-carP antibodies, which we posit may be a cross-
reactive subset of ACPAs.
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Additional file
Additional file 1: Supplementary tables and methods. Table S1 α-
enolase peptide sequences. Table S2 Association between PTPN22 poly-
morphism and RA in subgroups of patients, divided based on the pres-
ence/absence of anti-CEP-1 and anti-carb-CEP-1 IgG. (DOCX 22 kb)
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